Aligos Therapeutics (ALGS) Accounts Payables (2019 - 2026)
Aligos Therapeutics' (ALGS) quarterly Accounts Payables came in at $7.6 million in Q1 2026, up 71.28% YoY from $4.5 million in Q1 2025, and up 91.84% on a QoQ basis from $4.0 million in Q4 2025.
Aligos Therapeutics (ALGS) Accounts Payables (2019 - 2026) Analysis & Trends
Aligos Therapeutics (ALGS) has 8 years of Accounts Payables data on file, last reported at $7.6 million in Q1 2026.
- Quarterly Accounts Payables rose 71.28% year-over-year to $7.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.6 million (up 71.28% YoY) and the FY2025 annual result came in at $4.0 million, up 54.88% from the prior year.
- Accounts Payables climbed to $7.6 million in Q1 2026, from $4.0 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $7.6 million in Q1 2026 to a low of $2.5 million in Q4 2023.
- A 5-year average of $3.8 million and a median of $3.2 million in 2023 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2023 — Accounts Payables tumbled 46.87% — and 2024, when it surged 110.4%.
- Tracing ALGS's Accounts Payables over 5 years: stood at $4.7 million in 2022, then plunged by 46.87% to $2.5 million in 2023, then climbed by 2.15% to $2.6 million in 2024, then soared by 54.88% to $4.0 million in 2025, then jumped by 91.84% to $7.6 million in 2026.
- The last three Accounts Payables figures came in at $7.6 million (Q1 2026), $4.0 million (Q4 2025), and $4.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 108.02 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 428.93 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 35.57 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 622.65 Mn |
| 10 | Aligos Therapeutics | 67.38 Mn | 36.94 Mn | - | 6.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.43 Mn |
| Mar 31, 2026 | 7.64 Mn |
| Dec 31, 2025 | 3.98 Mn |
| Sep 30, 2025 | 4.65 Mn |
| Jun 30, 2025 | 3.94 Mn |
| Mar 31, 2025 | 4.46 Mn |
| Dec 31, 2024 | 2.57 Mn |
| Sep 30, 2024 | 2.74 Mn |
| Jun 30, 2024 | 6.82 Mn |
| Mar 31, 2024 | 2.84 Mn |
| Dec 31, 2023 | 2.52 Mn |
| Sep 30, 2023 | 2.94 Mn |
| Jun 30, 2023 | 3.24 Mn |
| Mar 31, 2023 | 2.82 Mn |
| Dec 31, 2022 | 4.74 Mn |
| Sep 30, 2022 | 2.93 Mn |
| Jun 30, 2022 | 2.76 Mn |
| Mar 31, 2022 | 3.76 Mn |
| Dec 31, 2021 | 3.02 Mn |
| Sep 30, 2021 | 2.60 Mn |